Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximab
- 1 April 2005
- journal article
- review article
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 34 (5) , 34-38
- https://doi.org/10.1016/j.semarthrit.2005.01.009
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Tumor necrosis factor signalingCell Death & Differentiation, 2003
- Safety and Efficacy of Disease-Modifying Anti-Rheumatic AgentsDrug Safety, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Restraining mycobacteria: Role of granulomas in mycobacterial infectionsImmunology & Cell Biology, 2000
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisPublished by Elsevier ,1999
- An Antimicrobial Activity of Cytolytic T Cells Mediated by GranulysinScience, 1998
- Estimation of the Annual Risk of Tuberculous Infection for White Men in the United StatesThe Journal of Infectious Diseases, 1997
- Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in miceImmunity, 1995
- Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functionsCytokine, 1995
- The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infectionCell, 1989